New hope against deadly mold infections: generic drug shows promise
NCT ID NCT07239765
First seen Nov 20, 2025 · Last updated Jun 19, 2026 · Updated 29 times
Summary
This study tested a generic version of an antifungal drug called Amphotericin B Cholesteryl Sulfate Complex (ABCD) in 67 adults with invasive mold disease, a serious infection. The goal was to see if the drug is safe and works well. Participants received the drug through an IV, and researchers tracked side effects and how many completed treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE MOLD DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital Of Guangzhou Medical University
Guangzhou, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Amphotericin B Cholesteryl Sulfate Complex (ABCD)
What this could lead to
If successful, this could provide a new generic treatment option for serious mold infections, potentially improving access and outcomes.
What could go wrong
This is a completed Phase 3 trial with only 67 participants, so results may not apply to all patients. Amphotericin B can cause kidney problems and infusion reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.